The United States vs. Other Countries: Availability of New Medicines Varies



Government price setting policies insert politicians and bureaucrats between patients and their doctors. It means the government decides what your medicines are worth and what diseases are worth investing in, leading to restricted access to medicines. Here is how some OECD countries stack up.

		New Medicines Available	Average Delay in Availability of New Medicines
₩.•.	New Zealand	16%	33 months
	Mexico	25%	25 months
	Korea	33%	28 months
***	Australia	34%	21 months
	Ireland	35%	21 months
	Belgium	41%	23 months
۲	Portugal	42%	18 months
-1-	Switzerland	43%	18 months
<u>.</u>	Spain	43%	23 months
•	Slovenia	43%	19 months
*	Canada	45%	17 months
	Netherlands	45%	19 months
	Sweden	46%	15 months
	Finland	48%	15 months
	Japan	51%	15 months
	Italy	52%	20 months
	France	52%	20 months
	Denmark	53%	12 months
	Norway	55%	13 months
	Austria	56%	12 months
	United Kingdom	59%	12 months
	Germany	61%	11 months
	United States	85%	0-4 months

Source: PhRMA, "Global Access to New Medicines Report," 2023, available at https://phrma.org/en/resourcecenter/Topics/Access-to-Medicines/Global-Access-to-New-Medicines-Report